|
|
Blood, 15 August 2005, Vol. 106, No. 4, pp. 1164-1174.
Prepublished online as a Blood First Edition Paper on April 26, 2005; DOI 10.1182/blood-2005-02-0687.
 Previous Article | Table of Contents | Next Article 
REVIEWS IN TRANSLATIONAL HEMATOLOGY
Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach
Jeremy S. Abramson, and
Margaret A. Shipp
From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Abstract
Diffuse large B-cell lymphoma (DLBCL) displays striking heterogeneity at the clinical, genetic, and molecular levels. Clinical prognostic models can define a population at high risk for relapse following empiric chemotherapy, although such models do not account for underlying biologic differences among tumors. Commonly observed genetic abnormalities that likely contribute to pathogenesis include translocations of BCL6, BCL2, cMYC, and FAS(CD95) mutations, and aberrant somatic hypermutation. Despite recent advances in empiric chemotherapy, including interval reduction of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and the incorporation of anti-CD20 monoclonal antibodies, a significant proportion of patients still die of their disease. Gene expression profiling has shed light on the molecular heterogeneity within DLBCL by highlighting similarities between subsets of tumors and normal B cells, identifying features associated with unfavorable responses to empiric combination chemotherapy, and defining robust subtypes with comprehensive transcriptional signatures. Such strategies have suggested distinct routes to lymphomagenesis and have identified promising rational therapeutic targets. Additional novel therapies under investigation include those targeting BCL6 and BCL2, as well as development of novel monoclonal antibody-based therapies. Our increasing molecular understanding of the heterogeneous subsets within DLBCL will likely improve the current empiric therapy of DLBCL by identifying rational therapeutic targets in specific disease subtypes.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. Dai, X. F. Zhao, P. Hagner, P. Shapiro, K. Mazan-Mamczarz, S. Zhao, Y. Natkunam, and R. B. Gartenhaus
Extracellular Signal-Regulated Kinase Positively Regulates the Oncogenic Activity of MCT-1 in Diffuse Large B-Cell Lymphoma
Cancer Res.,
October 1, 2009;
69(19):
7835 - 7843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Li, S.-W. Kim, D. Rai, A. R. Bolla, S. Adhvaryu, M. C. Kinney, R. S. Robetorye, and R. C. T. Aguiar
Copy number abnormalities, MYC activity, and the genetic fingerprint of normal B cells mechanistically define the microRNA profile of diffuse large B-cell lymphoma
Blood,
June 25, 2009;
113(26):
6681 - 6690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, D. Rai, M. R. McKeller, and R. C. T. Aguiar
Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL
Blood,
June 11, 2009;
113(24):
6153 - 6160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A Engel and C. Lee
Sudden appearance and spontaneous regression of diffuse large B cell lymphoma in a man with a broken arm
BMJ Case Reports,
March 5, 2009;
2009(mar02_1):
bcr1020081036 - bcr1020081036.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. V. Lee, C. A. Green, O. G. Negrea, S. Dodson, S. K. Farrell, J. E. Hewitt, T. Jago, C. E. Ramsey, T. Cato, E. Crawford, et al.
B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP
Lab Med,
February 1, 2009;
40(2):
79 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sud and J. W. Friedberg
Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: impact of prior rituximab
Haematologica,
December 1, 2008;
93(12):
1776 - 1780.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res.,
November 1, 2008;
68(21):
8705 - 8714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-W. Kim, D. W. Oleksyn, R. M. Rossi, C. T. Jordan, I. Sanz, L. Chen, and J. Zhao
Protein kinase C-associated kinase is required for NF-{kappa}B signaling and survival in diffuse large B-cell lymphoma cells
Blood,
February 1, 2008;
111(3):
1644 - 1653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Niino, K. Tsukasaki, K. Torii, D. Imanishi, T. Tsuchiya, Y. Onimaru, H. Tsushima, S. Yoshida, Y. Yamada, S. Kamihira, et al.
Human Herpes virus 8-negative primary effusion lymphoma with BCL6 rearrangement in a patient with idiopathic CD4 positive T-lymphocytopenia
Haematologica,
January 1, 2008;
93(1):
e21 - e23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, J. Ouyang, S. Monti, S. J. Rodig, K. Takeyama, J. Abramson, W. Chen, J. L. Kutok, G. A. Rabinovich, and M. A. Shipp
The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma
PNAS,
August 7, 2007;
104(32):
13134 - 13139.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-Y. Liu, C. Leboeuf, J.-Y. Shi, J.-M. Li, L. Wang, Y. Shen, J.-F. Garcia, Z.-X. Shen, Z. Chen, A. Janin, et al.
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma
Blood,
July 1, 2007;
110(1):
339 - 344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
May 1, 2007;
25(13):
1741 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-F. Qi, J. X. Zhou, C. H. Lee, Z. Naghashfar, S. Xiang, A. L. Kovalchuk, T. N. Fredrickson, J. W. Hartley, D. C. Roopenian, W. F. Davidson, et al.
Anaplastic, Plasmablastic, and Plasmacytic Plasmacytomas of Mice: Relationships to Human Plasma Cell Neoplasms and Late-Stage Differentiation of Normal B Cells
Cancer Res.,
March 15, 2007;
67(6):
2439 - 2447.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Shipp
Molecular Signatures Define New Rational Treatment Targets in Large B-Cell Lymphomas
Hematology,
January 1, 2007;
2007(1):
265 - 269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Juszczynski, J. L. Kutok, C. Li, J. Mitra, R. C. T. Aguiar, and M. A. Shipp
BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate.
Mol. Cell. Biol.,
July 1, 2006;
26(14):
5348 - 5359.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takahashi, F. Feuerhake, J. L. Kutok, S. Monti, P. Dal Cin, D. Neuberg, J. C. Aster, and M. A. Shipp
FAS Death Domain Deletions and Cellular FADD-like Interleukin 1{beta} Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes.
Clin. Cancer Res.,
June 1, 2006;
12(11):
3265 - 3271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Abramson
T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.
Oncologist,
April 1, 2006;
11(4):
384 - 392.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Pasqualucci, M. Compagno, J. Houldsworth, S. Monti, A. Grunn, S. V. Nandula, J. C. Aster, V. V. Murty, M. A. Shipp, and R. Dalla-Favera
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
J. Exp. Med.,
February 20, 2006;
203(2):
311 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Sehn
Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma
Hematology,
January 1, 2006;
2006(1):
295 - 302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
